Drugs / epigallocatechin-3-gallate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06924749 | Jun 2023 → Jun 2024 | pneumonia | Shandong Cancer Hospital and Institute | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epigallocatechin-3-gallate | “Our initial Phase I/II clinical trial has showed that epigallocatechin-3-gallate (EGCG), a catechin monomer isolated from tea, exhibits favorable safety profiles with...” PMID 41549240 ↗ Jan 2026 |
| Known as | EGCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06924749 ↗ |
| Route | Inhaled | “10ml is inhaled by atomization three times a day” NCT06924749 ↗ |